practical oncology mast cell tumor
DESCRIPTION
Practical Oncology Mast Cell Tumor. Wendy Blount, DVM. Mast Cell Tumor. Mast cell granules contain histamine and heparin, among other things Degranulation is largely responsible for symptoms Release of histamine Increased gastrin secretion (anorexia, ulcers, hematemesis) - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/1.jpg)
Practical OncologyMast Cell Tumor
Wendy Blount, DVM
![Page 2: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/2.jpg)
Mast Cell Tumor
• Mast cell granules contain histamine and heparin, among other things
• Degranulation is largely responsible for symptoms
• Release of histamine– Increased gastrin secretion (anorexia, ulcers,
hematemesis)– Anaphylactoid reaction
• Release of heparin – less clinically significant
![Page 3: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/3.jpg)
Mast Cell Tumor• Most often found on the skin– Most common skin tumor in the dog– Brachycephalics & retrievers predisposed
• 2nd most common cancer in dogs• Also visceral & elsewhere– Gastrointestinal, Spleen, bone marrow
• Less common sites– Oropharyngeal– Mediastinum– CNS– Nail bed, ocular & periocular
![Page 4: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/4.jpg)
Mast Cell Tumor• Can have many different appearances• Can be infiltrated with fat• Symptoms can be waxing and waning• Tumor gets bigger and smaller over time• 5-15% have multiple masses at
presentation• 20-50% will have more MCT in the future,
even if the first are cured
![Page 5: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/5.jpg)
Etiology• Allergic skin disease?• C-KIT mutation (aka SCFR, CD117)– In “high risk MCT” (high grade II & all grade III)– These have decreased survival time– can be treated with tyrosine kinase inhibitors
(Palladia & Kinavet-CA1 )– SCFR – stem cell factor receptor– C-KIT normally regulates proliferation,
migration and differentiation– When C-KIT is mutated, it is constantly turned
on, dysregulating cell growth an promoting malignancy
![Page 6: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/6.jpg)
Clinical Signs• GI Signs– Anorexia, vomiting, melena
• Pruritus and skin flushing• Facial swelling• Weakness, lethargy• Delayed wound healing• Darier’s Sign– swollen, itchy, red skin after scratching or
stroking the skin
![Page 7: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/7.jpg)
• GI Signs– Anorexia, vomiting, melena
• Pruritus and skin flushing• Facial swelling• Weakness, lethargy• Delayed wound healing• Darier’s Sign– swollen, itchy, red skin after scratching or
stroking the skin
Clinical Signs
![Page 8: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/8.jpg)
Staging for Metastasis
Eva GeromeBonham TX
Chris Longo – Diamondhead, MS
Melanie Enger, - Lufkin TX
![Page 9: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/9.jpg)
Diagnosis• FNA Cytology often diagnostic– Round cells with or without granules– Granules intracellular or in background– Granules form a halo around the relatively
pale nucleus– eosinophils
• Give diphenhydramine before or right after aspiration– FNA can cause degranulation – Dexamethasone as well if mass is visibly
inflamed
![Page 10: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/10.jpg)
Diagnosis• FNA Cytology often diagnostic– Round cells with or without granules– Granules intracellular or in background– eosinophils
• Give diphenhydramine before or right after aspiration– FNA can cause degranulation – Dexamethasone as well if mass is visibly
inflamed
![Page 11: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/11.jpg)
Diagnosis• FNA Cytology often diagnostic– Round cells with or without granules– Granules intracellular or in background– eosinophils
• Give diphenhydramine before or right after aspiration– FNA can cause degranulation – Dexamethasone as well if mass is visibly
inflamed
![Page 12: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/12.jpg)
Diagnosis• FNA Cytology often diagnostic– Round cells with or without granules– Granules intracellular or in background– eosinophils
• Give diphenhydramine before or right after aspiration– FNA can cause degranulation – Dexamethasone as well if mass is visibly
inflamed
![Page 13: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/13.jpg)
Diagnosis• FNA Cytology often diagnostic– Round cells with or without granules– Granules intracellular or in background– eosinophils
• Give diphenhydramine before or right after aspiration– FNA can cause degranulation – Dexamethasone as well if mass is visibly
inflamed
![Page 14: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/14.jpg)
Staging for Metastasis• Histopathology for grading– Excisional if resectable– Incisional if not
• FNA draining lymph node– Clusters of mast cells likely metastasis– Single mast cells likely not
• Abdominal US with FNA liver and spleen• CBC, panel, buffy coat
![Page 15: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/15.jpg)
Staging for Metastasis• Non-resectable MCT
![Page 16: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/16.jpg)
Staging for Metastasis• Non-resectable MCT
![Page 17: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/17.jpg)
Staging for Metastasis• Non-resectable MCT
![Page 18: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/18.jpg)
Staging for Metastasis• Lymph node cytologies
![Page 19: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/19.jpg)
Staging for Metastasis• Lymph node cytologies
![Page 20: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/20.jpg)
Staging for Metastasis• Lymph node cytologies
![Page 21: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/21.jpg)
Tumor Stage (WHO)• Stage 0 – microscopic disease only• Stage I – tumor confined to the dermis• Stage II – tumor does not infiltrate
subcutaneous tissues, lymph node metastasis
• Stage III – large, infiltrating tumor or multiple tumors
• Stage IV – distant metastasisConsideration is being given to reducing
stage of multiple dermal tumors
![Page 22: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/22.jpg)
Histopathology• grade• Mitotic Index (MI)• Surgical margins – clean, narrow or dirty• Invasiveness – dermal or invasive
(subcutaneous/muscle)
Histopathology tells a great deal about prognosis and treatment indicated
![Page 23: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/23.jpg)
Histopathologic Grading• Grade I – well differentiated, behaves benignly• Grade II – intermediate differentiation,
behavior is widely variable– Low grade II – often behaves benignly– High grade II – C-kit mutation, often behaves
malignantly– Determined by MSU prognostic panel (form)
• Grade III – anaplastic, aggressive behaviorThis is the Patnaik SystemObsolete system has grade I the worst and grade
III the best prognosis
![Page 24: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/24.jpg)
Surgery• Mainstay of low grade MCT treatment• Mast Cell Tumors often extend well beyond
the visible mass• Diagnose by FNA before you excise• Lateral margins 2-3 cm beyond visible mass– Small tumors <1 cm, 1.5-2cm margins may be
adequate• One fascia layer deep to visible mass• Avoid manipulating the tumor• Intraoperative cytologies on 4 lateral and
deep margins can be helpful
![Page 25: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/25.jpg)
SurgeryPrednisone for pre-surgical cytoreduction• Out of favor by oncologists at this time• I still like use it– Stabilizes lysosomal membranes – may
prevent degranulation caused by surgery– Controls inflammation around the tumor so
tumor borders are easier to see– Usually makes the dog feel better, so client
perceives better toleration of surgery• Prednisone 40 mg/m2 PO SID x 7days, then
QOD
![Page 26: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/26.jpg)
SurgeryRe-excision where borders are dirty on
grade I or II• Grade III tumors considered systemic– More surgery only for local palliation
• 3 cm beyond original surgery• One fascia layer deeper than original
surgery• Complete resection results in long survival• If clean borders, 95% cured with second
excision, using these rules
![Page 27: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/27.jpg)
SurgeryNeoAdjuvant Therapy• Given to a patient with non-resectable
tumor in hopes of making it resectable• Chemotherapy and/or radiation• Best managed by medical and/or radiation
oncologists• Need to understand effects of neoadjuvant
therapy on healing and when and how to do surgery
![Page 28: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/28.jpg)
Sandra Goodwin – Forney TXSandra Goodwin’s Compadre
Betsy Hoffman Robinson – League City TX
![Page 29: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/29.jpg)
Chemotherapy• Not indicated for multiple dermal MCT
that are cured by excision• To deal with MCT at the tumor borders
when radiation not possible• To improve post-surgical prognosis for high
risk grade II and all grade III MCT• To palliate metastatic or systemic disease• Surprisingly, there are few studies to
evaluate efficacy of various protocols
![Page 30: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/30.jpg)
ChemotherapyVinblastine and prednisone (VP)• Median survival 134 days (5 months) – gross disease
after surgery• Median survival 1013 days (3 years) – microscopic
disease after surgery• 45% survival at 2 years• Half of these had surgery prior to chemo• This has not been my experience with grade III
– Most dead in 2-4 months– All gone within the year
• Vinblastine 2-2.2 mg/m2 IV over 10 min once weekly for 4 weeks, then every other week for 4 doses
• Prednisone 40 mg/m2 PO SID x 2 weeks then QOD
![Page 31: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/31.jpg)
ChemotherapyCCNU• 60-70 mg/m2 PO q3-4 weeks– 4 week interval the first time, then shorten if
symptoms return during the 4th week– Baseline liver tests (ALT, SAP, albumin)– Pretreat with diphenhydramine
• Check before 3rd dose and then prior to each• Stop if signs of liver disease to prevent liver
failure• 6-8 doses common maximum– I have reached 12 at most
• Grade III median survival 2 months
![Page 32: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/32.jpg)
ChemotherapyAlternating VP and CCNU• Alternate vinblastine and CCNU every 2 weeks
for a total of 8 treatments– Doses on previous slides
• Prednisone 2 mg/kg PO SID tapered gradually to maintenance dose of 0.5 mg/kg PO SID x 6 months
• Macroscopic disease grades II and III– 3 remission, 4 PR– median duration of response 58 days
• 2 patients did not reach 4th CCNU treatment due to ALT >1000
![Page 33: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/33.jpg)
ChemotherapyVinblastine, prednisone, cyclophosphamide• Study on high risk MCT• Median progression free interval of more
than 2 years• Median survival 6 years• Grade III and those who needed reduction
of vinblastine dose did not do as well• New protocol, but this may become a
popular protocol in the future
![Page 34: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/34.jpg)
Chemotherapy• Vincristine alone not effective for MCT• COP can work well for grade II MCT• Many dirty border grade II do very well
with most protocols– many months, years or cured
• Some grade II with dirty borders spontaneously resolve– Are malignant MCT indistinguishable from
inflammatory reaction?
![Page 35: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/35.jpg)
Chemotherapy• Because of the VP study, most oncologists
prefer VP to CCNU or both for grade III• My experience is that outcome is similar
with all 3 protocols for grade III MCT– Palliative therapy often does just as well– A significant proportion do not respond at all
![Page 36: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/36.jpg)
Chemotherapy
![Page 37: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/37.jpg)
ChemotherapyPalladia and Kinavet-CA1/Masivet• Tyrosine kinase (TKI) inhibitors• Prednisone and TKI are the chemo drugs
with direct cytotoxicity for MCT– Probably the most effective chemo for high
grade MCT • Not appropriate for low grade MCT due to
toxicityA game changer for high grade very large
MCT
![Page 38: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/38.jpg)
ChemotherapyPalladia and Kinavet-CA1/Masivet• 25% of grade II & III MCT have C-KIT
mutation• Blocking wild type or mutated KIT causes
apoptosis in MCT• antiproliferative through KIT blockade• antiangiogenic through other MOA
![Page 39: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/39.jpg)
ChemotherapyPalladia and Kinavet-CA1/Masivet• Indications for use:– Dogs >11-15 lbs only (not cats)– Non-resectable MCT• Dirty borders after re-excision
– Multiple diffuse or coalescing high grade MCT– Concurrent conditions precluding surgery or
multiple sedations for radiation therapy– High grade MCT or C-KIT mutation– Indicated with or without metastasis – Post Chemo – VP x 4 weeks, then Palladia
![Page 40: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/40.jpg)
ChemotherapyPalladia and Kinavet-CA1/Masivet• Though both are TKIs, there can be resistance
to one but not the other– If one fails, try the other– Stable disease is a victory with either
• Palladia has more broad spectrum activity, and is thought to be more likely to cause clinical response than Kinavet
• Kinavet response can take up to 2-3 weeks• Gleevec is a TKI used in people, but it is very
expensive ($100-150 per pill)– Palladia $6-800, Kinavet $500 /month - 70lb dog
![Page 41: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/41.jpg)
ChemotherapyKinavet Administration• 12.5 mg/kg PO SID– Dose chart on package insert (Client Info)– Cannot be used in dogs weighing less than 15
pounds• Dose reduction in response to adverse events– stop Kinavet for 1-2 weeks– Reduce dose to 9 mg/kg/day when resumed
• Weekly CBC/panel for the first 6 weeks– Then every 3 weeks x 2– Then every 6 weeks thereafter
![Page 42: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/42.jpg)
ChemotherapyPalladia Administration• 3.25 mg/kg PO QOD (or MWF)– Dose chart on package insert– With or without food
• Dose reduction in response to adverse events– Stop Palladia for 1-2 weeks– 0.5 mg/kg reduction when reduced– Minimum dose 2.2 mg/kg PO QOD
• Weekly CBC/panel for the first 6 weeks– Then every 3 weeks x 2– Then every 6 weeks thereafter
![Page 43: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/43.jpg)
ChemotherapyPalladia Administration• GI side effects common– Make sure owner knows to STOP drug if
anorexia, vomiting, diarrhea• Dispense Cerenia and metronidazole at
the first visit to have on hand• Administer H1 and H2 blockers
concurrently
![Page 44: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/44.jpg)
ChemotherapyPalladia Study – Bergman & Clifford, 2009
• Dogs with progressive disease on the blinded phase could enter open-label phase at any time
![Page 45: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/45.jpg)
ChemotherapyPalladia Study – Bergman & Clifford, 2009• Statistically significant improvement in
objective response rate
![Page 46: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/46.jpg)
ChemotherapyPalladia Study – Bergman & Clifford, 2009• 57.2% did not respond• Among responders, median duration of
response was 12 weeks• Median time to non-response or death was 18
weeks• 82% of dogs with C-KIT mutation responded• 54% of dogs without mutation responded• There was a placebo response– Likely due to spontaneously resolving degranulation
• Clin Cancer Res 2009; 15:3856-3865.
![Page 47: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/47.jpg)
ChemotherapyPalladia Side effects
![Page 48: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/48.jpg)
ChemotherapyPalladia Side effects• Dec. albumin – 13% Palladia, 8% Placebo• Palladia given long term leads to
glomerular disease and renal failure
![Page 49: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/49.jpg)
ChemotherapyKenneth Kimbrough – Longview TXStephen Garner – Nacogdoches TX
![Page 50: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/50.jpg)
ChemotherapyKinavet-CA1
![Page 51: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/51.jpg)
ChemotherapyKinavet-CA1
![Page 52: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/52.jpg)
ChemotherapyPalliative therapy• Prednisone 40 mg/m2/day– Wean gradually to 0.5 mg/m2/day
• Antihistamines daily• H2 blocker or proton pump blocker– Cimetidine, ranitidine, famotidine– Omeprazole, esomeprazole
• sucralfate if ulcerated – Hematemesis, melena
![Page 53: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/53.jpg)
Radiation Therapy
• Non-resectable high grade MCT• Regional lymph node metastasis• Grade II Stage 0 MCT with dirty margins– Disease free interval is increased compared to
no treatment– Similar outcome to re-excision if it is possible
• No indication to irradiate grade II MCT with clean borders
![Page 54: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/54.jpg)
Treatments Not Recommended
• Deionized water injections– At one time recommended for cytoreduction
prior to surgery– Subsequent studies have proven ineffective– Risk causing degranulation– Pain on injection
• intralesional Vetalog or DepoMedrol– Reserved for those dogs who have too many
dermal MCT to remove and no evidence of systemic disease
![Page 55: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/55.jpg)
Prognosis• Stage and grade much more important than
with LSA– Grade I with clean borders are cured by surgery– Low grade II clean borders usually cured by
surgery– High grade II clean borders should probably
have adjunctive chemo or radiation– High grade II with dirty borders should
definitely have adjunctive chemo and/or radiation and may have poor prognosis
– Virtually all of grade III die of their disease, often within a few months
![Page 56: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/56.jpg)
PrognosisIndicators of poor prognosis• Dirty borders on re-excision • High grade, advanced stage, MI >5• Breed- Shar pei• Systemic signs due to degranulation• Size and growth rate• Location – perineum, scrotum, nail bed,
mucocutaneous, muzzle• C-kit deletion and other histopath
prognostic indicators (MSU/AMC panels)
![Page 57: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/57.jpg)
PrognosisIndicators of better prognosis• Clean borders on excision• Low grade, low stage, MI <5• Breed – Boxers and Pugs
![Page 58: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/58.jpg)
PrognosisIndicators of better prognosis• Clean borders on excision• Low grade, low stage, MI <5• Breed – Boxers and Pugs
![Page 59: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/59.jpg)
PrognosisIndicators of better prognosis• Clean borders on excision• Low grade, low stage, MI <5• Breed – Boxers and PugsMultiple primary mast cell tumors do not
necessarily worsen prognosis• Dogs who tend to get one dermal MCT tend
to get more, simultaneously or sequentially• Warn owners to look for more when you
remove the first
![Page 60: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/60.jpg)
PrognosisAgNOR staining (MCT prognostic panel) • gives more information for grade II• Do chemo if high grade II• Amputate non-resectable low grade II• Cost is about $200 including shipping• Send MCT histopath to MSU or AMC, so you
can add the prognostic panel if grade II• Save center of tumor in formalin to send to
MSU /AMC for panel later if grade II• Can be difficult to get unstained paraffin
sections from the first lab (except TVMDL)
![Page 61: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/61.jpg)
Client Handout• Mast Cell Tumors• Chemo agents discussed Sunday
![Page 62: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/62.jpg)
Acknowledgements• Philip J. Bergman, DVM, MS, PhD, DACVIM
(Oncology)VIN Consultant, CMO BrightHeart Vet Centers
• Louis-Philippe de Lorimier, DVM, ACVIM (Oncology)VIN Consultant, U of Ill Urbana-ChampaignVisiting assistant professor, medical oncology
• Karri A. Meleo, DVM, ACVIM (Oncology), ACVRVIN Consultant, Vet Onc Serv, Edmonds, WA
![Page 63: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/63.jpg)
Acknowledgements• Robert C. Rosenthal, DVM, BS, MS, PhD
VIN Consultant
• Kurt R. Verkest, BVSc, BVBiol, MACVSc (Small Animal)VIN Associate Editor, Univ Queensland, Australia
• Claudia Barton, DVM, ACVIM (Internal Medicine, Oncology)
TAMU CVM
![Page 64: Practical Oncology Mast Cell Tumor](https://reader030.vdocuments.us/reader030/viewer/2022033102/56816717550346895ddb884f/html5/thumbnails/64.jpg)
Acknowledgements• Craig Clifford, DVM, MS, ACVIM (Oncology)
VIN Consultant